Identification of canine proBNP by immunoassay

• US 8,628,973 B2
• Filed: 09/08/2005
• Issued: 01/14/2014
• Est. Priority Date: 09/08/2004
• Status: Active Grant

• Current Assignee: The Antibody Lab GmbH
• Original Assignee: Biomedica Medizinprodukte GmbH & Co., KG
• Inventors: Woloszczuk, Wolfgang, Hawa, Gerhard
• Primary Examiner(s): FOSTER, CHRISTINE E
• Application Number:
  US10/596,968
• Publication Number:
  US 20070161041A1
• Time in Patent Office: 3,050 Days
• Field of Search: None
• US Class Current: 436/86
• CPC Class Codes: C07K 16/26 against hormones ; against hormone releasing or inhibiting factors
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: G01N 2333/58 Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92

Abstract

The invention relates to a method of determining feline or canine proBNP or fragments thereof, comprising the steps of

• • providing a feline or canine sample,
  • contacting the sample with at least one antibody which, when determining feline proBNP, or fragments thereof, respectively, binds to at least one epitope in the region comprising the amino acids 20 to 42 and/or in the region comprising the amino acids 57 to 80 of feline proBNP and, when determining canine proBNP, or fragments thereof, binds to at least one epitope in the region comprising the amino acids 20 to 86 of canine proBNP, and
  • determining the presence and/or concentration of the feline or canine proBNP, or fragments thereof, present in the sample.

Claims

1. A method of diagnosing cardiac insufficiency in a canine by detecting canine proBNP or a fragment thereof containing an epitope in the amino acid sequence of SEQ ID NO:

2, an epitope in the amino acid sequence of SEQ ID NO;

3, and an epitope in the amino acid sequence of SEQ ID NO;

5 in a canine sample, the method comprising;

contacting a canine blood sample with a first antibody that binds to an epitope in the amino acid sequence of SEQ ID NO;

2 of canine proBNP, a second antibody that binds to an epitope in the amino acid sequence of SEQ ID NO;

3 of canine proBNP, and a third antibody that binds to an epitope in the amino acid sequence of SEQ ID NO;

5 of canine proBNP;

detecting the canine proBNP or a fragment thereof containing an epitope in the amino acid sequence of SEQ ID NO;

2, an epitope in the amino acid sequence of SEQ ID NO;

3, and an epitope in the amino acid sequence of SEQ ID NO;

5 present in the sample by detecting the binding of the antibodies to the epitopes;

comparing the amount of the canine proBNP or fragment thereof in the sample with the amount of canine proBNP or fragment thereof in a blood sample from a healthy canine; and

diagnosing cardiac insufficiency in the canine from which the sample was obtained if the amount of the canine proBNP or fragment thereof in the sample is higher than the amount of canine proBNP or fragment thereof in a sample from the healthy canine.

2. The method of claim 1, wherein the epitopes comprise at least 3 amino acids.

3. The method of claim 1, wherein the first, second, and third antibodies are polyclonal.

4. The method of claim 1, wherein the first antibody, the second antibody, and/or the third antibody is labeled.

5. The method of claim 4, wherein the label is a peroxidase, biotin, fluorescent dye, gold colloid, or a radionuclide.

6. The method of claim 1, wherein the first antibody, the second antibody, or the third antibody is bound to a solid phase.

7. The method of claim 1, wherein the determination of the canine proBNP or fragment thereof comprises radioimmunoassay, immune binding assay, Western blot, immunohistochemistry, enzyme immunoassay, and/or a lateral flow device.

8. The method of claim 1, wherein the first, second, and third antibodies are monoclonal.

9. The method of claim 1, wherein the blood sample is serum.